Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697588 | 0.88 | TAAR1 (0.43) | TAAR1IDO1LIPGCYP2D6CYP2C9 | |
| SCHEMBL808984 | 0.82 | TAAR1 (0.47) | TAAR1IDO1LIPGCYP2D6CYP2C9 | |
| SCHEMBL808974 | 0.79 | IAPP (0.46) | TAAR1IDO1CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL6072678 | 0.79 | TAAR1 (0.41) | TAAR1IDO1LIPGCYP2D6CYP2C9 | |
| SCHEMBL4181180 | 0.75 | TAAR1 (0.56) | TAAR1IDO1LIPGCYP2D6CYP2C9 | |
| SCHEMBL29712399 | 0.75 | TAAR1 (0.47) | TAAR1IDO1CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL809020 | 0.75 | TAAR1 (0.47) | TAAR1IDO1CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL6691667 | 0.75 | IAPP (0.47) | TAAR1LIPGCYP2D6CYP2C9CYP1A2 | |
| SCHEMBL12812877 | 0.74 | TAAR1 (0.50) | TAAR1IDO1CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL14302122 | 0.74 | LIPG (0.55) | TAAR1IDO1LIPGTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776119-B9 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2012-06-13 | — | — | EP | disclosed |
| EP-1776119-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2012-01-18 | — | — | EP | disclosed |
| US-7902224-B2 | Tetrahydro-naphthalene derivatives as glucocorticoid receptor modulators | GLAXO GROUP LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20070224130-A1 | Tetrahydro-Naphthalene Derivatives as Glucocorticoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | disclosed |
| EP-1776119-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006015870-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070224130-A1 | Tetrahydro-Naphthalene Derivatives as Glucocorticoid Receptor Modulators | NR3C1, NR3C2, MC2R | TAAR1 1037/4885IDO1 1955/4885LIPG 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.